Lung Cancer Information Center
Lung cancer is the second most commonly diagnosed cancer among both men and women in the United States. Each year, more than 114,000 men and more than 100,000 women will be diagnosed with lung cancer. There are an estimated 360,000 lung cancer survivors living in the U.S. today.
Although long-term survival with lung cancer remains poor, progress is being made in lung cancer treatment. Advances in surgery, chemotherapy, radiation therapy, and targeted therapy are all contributing to improved lung cancer survival. In addition, advances in supportive care have made lung cancer treatment more tolerable, leading to improved quality of life.
Understanding lung cancer treatment options, the role of different doctors specializing in the treatment of lung cancer, and how and when to access new and innovative lung cancer treatment options available through clinical trials is essential in order to achieve the best outcome from lung cancer treatment.
The Cancer Consultants Lung Cancer Information Center has been designed to help patients understand lung cancer and lung cancer treatment options while providing ongoing information, inspiration, support, and community to individuals affected by a diagnosis of lung cancer.
Headline Lung Cancer News 
Approximately 16% of Worldwide Cancers Caused By Preventable Infections
About 16% of cancers worldwide are the result of preventable and treatable infections.
Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer
Overall health is an important factor when considering treatment of older people with non-small cell lung cancer.
Aspirin Continues to Look Promising for Cancer Prevention
Study reports fewer cases and fewer deaths with daily use.
Lung Cancer Tips
Men, Fertility, and Cancer Men who confront a cancer diagnosis before beginning or completing their families...
Women, Fertility and Cancer Women who confront a cancer diagnosis before beginning or completing their families...
What is Genomics? You’ve probably heard of genetic testing for cancer susceptibility, but the more...
Lung Cancer Management
Inspiration, Hope & Resources
Lung Cancer Alliance By Diana Price Laurie Fenton Ambrose, president and CEO of the Lung Cancer Alliance...
A Legacy of Compassion and Commitment The Joan Scarangello Foundation to Conquer Lung Cancer by Diana Price Summer...
Jack & Jill Late Stage Cancer Foundation Jon Albert, founder of the Jack & Jill Late Stage Cancer Foundation shows the...
Lung Cancer Clinical Trials
INST0712C – A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously-Treated Lung Cancers
H3E-MC-JMHD – Randomized, Open-label, Phase 3 study of Pemetrexed plus Carboplatin and Bevacizumab versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Non-Small Cell Lung Cancer
07-050 – A randomized, open-label, multinational phase III trial comparing amrubicin versus topotecan in patients with extensive or limited and sensitive or refractory small cell lung cancer (SCLC) after failure of first-line chemotherapy.
 |
 |
 |
 |
